Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Zenas granted options for 225,000 shares to newly hired employees
- ➤Zenas granted 9,000 restricted stock units to newly hired employees
- ➤Options carry a $27.93 exercise price and ten-year term
- ➤Options and RSUs vest over four years under Nasdaq inducement rules
WALTHAM, Mass., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 225,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 9,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Stock Options have a ten-year term and an exercise price per share of $27.93, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of November 15, 2027, November 15, 2028, November 15, 2029 and November 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.
Get started
Create a free account to read the full story.
